Bristol Myers Squibb (BMY) stock
Last close $58.34 on 2026-11-19 (-2.05%) · Sector: Healthcare
Bristol Myers Squibb is a large American drugmaker headquartered in New York City that researches, makes, and sells prescription medicines for serious diseases such as cancer, blood clots, and immune disorders. It earns most of its money by selling these medicines around the world, and it spends a large share of its revenue on research to develop new ones.
Bristol Myers Squibb is still growing slowly, with revenue up 4.2% and a gross margin of 69.2%, meaning most of each sales dollar is left after the direct cost of making the medicine. Over the past year the stock rose 27.0%, well ahead of the S&P 500's 9.7% gain. The shares are currently 5.2% below their 50-day average and 3.5% below their 200-day average, and they sit 15.0% under their 52-week high. Three insiders sold about $0.7M of stock in the last 90 days and none bought, and the shares rose the day after all four recent earnings reports.
Key numbers
- Market cap: $119.8B
- Revenue (last 12 months): $50.03B
- Revenue growth: +4.2%
- Gross margin: 69.2%
- P/E: 12.9
- P/S: 2.4
- Debt to equity: 1.79
- Current ratio: 1.59
Quality score
Overall 26/100 · growth 33 · profitability None · financial health 1 · value 44
Performance and risk
1-year return +27.0% vs S&P 500 +9.7% · volatility 27.8% (S&P 500 13.8%) · largest drop -16.8% · beta 0.28
Stock move the day after earnings
- 2026-02-05: +3.3%
- 2026-04-30: +5.2%
- 2026-07-30: +2.8%
- 2026-10-29: +1.4%
Insider trades (12 months)
Bought $0.0M · sold $2.5M
BMY stock research · BMY options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.